Today’s time-consuming diagnosis of sepsis leads to prolonged patient hospitalization, increased mortality, and an overuse of broad spectrum antibiotics. Q-linea’s fully automated solutions cuts the diagnostic time for sepsis and deliver clinically-actionable results in hours instead of days.
ASTar™ will deliver answers about antibiotic susceptibility within three to six hours directly from positive blood cultures. The ASTrID® platform will identify the disease causing pathogen directly from venous blood and deliver an antibiotic susceptibility profile in ten hours. Both systems will report true minimal inhibitory concentration values.
Rapid AST directly from blood culture
ASTar™ is a fully automated, "load-and-go", instrument for Antibiotic Susceptibility Testing (AST), giving a susceptibility profile within three to six hours directly from a positive blood culture. ASTar shortens time to result, enabling early use of antibiotics specifically targeting the disease causing pathogen.
Sepsis is a disease growing in prevalence – early discovery and diagnostics will be key to its management. By using a technology that eliminates the need for traditional blood cultures the ASTrID® platform will shorten the current lead times in sepsis treatment by several days. The ASTrID platform is currently under development.
UPPSALA, Sverige, 12 november, 2018 – Q-linea AB, ett diagnostikbolag inriktat på att utveckla och leverera lösningar för snabb och korrekt diagnos av infektionssjukdomar. Q-linea AB (publ) (”Bolaget”)… Read more
Q-linea AB (publ) (“Q-linea” eller “Bolaget”), ett forsknings-, utvecklings- och tillverkningsbolag som primärt utvecklar instrument och förbrukningsartiklar för snabb infektionsdiagnostik, offentliggör idag sin avsikt att genomföra ett erbjudande… Read more
Q-LINEA INTENDS TO LIST ITS SHARES ON NASDAQ STOCKHOLM
November 11
Q-linea AB (publ) (“Q-linea” or the “Company”), a research, development, and manufacturing company that primarily develops instruments and disposables for rapid infection diagnostics, today announces its intention to… Read more
